LOS ANGELES--(EON: Enhanced Online News)--Goldberg Law PC announces the filing of a class action lawsuit against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) (Nasdaq: SCYX). Investors who purchased or otherwise acquired SCYNEXIS shares between May 2, 2014, and March 2, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 8, 2017 lead plaintiff deadline.
“[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study.”
If you purchased or otherwise acquired SCYNEXIS shares and would like more information regarding the class action lawsuit, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
On March 2, 2017, SCYNEXIS revealed that the U.S. Food and Drug Administration ("FDA") has issued a hold on clinical trials for the intravenous formulation of the Company’s lead product candidate SCY-078 “until the FDA completes a review of all available pre-clinical and clinical data.”
SCYNEXIS informed shareholders that “[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study.”
When this information was revealed to investors, the value of SCYNEXIS fell, causing investors harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.